Abstract
TO THE EDITOR: I read with great interest the article by Muller-Lissner et al. regarding safety, tolerability, and efficacy of tegaserod in patients with chronic constipation (1). A number of studies have addressed safety issues regarding tegaserod in several indications. However, for any drug, another important measure of safety is the frequency of drug interactions, for which the present study, like the previous ones, also gives no information. The data in hand regarding tegaserod-related drug interactions are limited and restricted to animal studies and individual cases. The authors state in the article that, at baseline, current medications were used as exclusion criteria only when related to intestinal motility, which means that some of the participants were already under medications for other reasons.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
